2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Proton Pump

Proton Pump

Proton Pump

Related Products

PDF 0.87 MB

Proton pump is an integral membrane protein that is capable of moving protons across a biological membrane. Mechanisms are based on conformational changes of the protein structure or on theQ cycle. In cell respiration, the proton pump uses energy to transport protons from the matrix of the mitochondrion to the inter-membrane space. It is an active pump, that generates a protonconcentration gradient across the inner mitochondrial membrane, because there are more protons outside the matrix than inside. The difference in pH and electric charge (ignoring differences inbuffer capacity) creates an electrochemical potential difference that works similar to that of a battery or energy storing unit for the cell. The process could also be seen as analogous to cycling uphill or charging a battery for later use, as it produces potential energy. The proton pump does not create energy, but forms a gradient that stores energy for later use.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-17507B
    Pantoprazole sodium hydrate
    		Inhibitor 99.93%
    Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI). Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142).
    Pantoprazole sodium hydrate
  • HY-146074
    RUVBL1/2 ATPase-IN-1
    		Inhibitor 99.63%
    RUVBL1/2 ATPase-IN-1 (compound 18) is a potent and selective inhibitor of RUVBL1/2 ATPase with IC50 values of 6.0 and 7.7 μM, respectively. RUVBL1 and RUVBL2 are highly conserved AAA ATPases (ATPases Associated with various cellular Activities) and highly relevant to the progression of cancer. RUVBL1/2 ATPase-IN-1 has the potential for the research of cancer diseases.
    RUVBL1/2 ATPase-IN-1
  • HY-A0213A
    Tiludronate disodium
    		Inhibitor 99.84%
    Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties.
    Tiludronate disodium
  • HY-117025A
    Manzamine A hydrochloride
    		Inhibitor 99.66%
    Manzamine A hydrochloride, an orally active beta-carboline alkaloid, inhibits specifically GSK-3β and CDK-5 with IC50s of 10.2 μM and 1.5 μM, respectively. Manzamine A hydrochloride targets vacuolar ATPases and inhibits autophagy in pancreatic cancer cells. Manzamine A hydrochloride has antimalarial and anticancer activities. Manzamine A hydrochloride also shows potent activity against HSV-1.
    Manzamine A hydrochloride
  • HY-103261
    SCH28080
    		Inhibitor 99.0%
    SCH28080 is a reversible, K+-competitive inhibitor of the gastric H,K-ATPase, with a Ki of 0.12 μM. SCH28080 is an effective inhibitor of acid secretion in vivo and with anti-gastric ulcer activity.
    SCH28080
  • HY-B0113S
    Omeprazole-d3
    		Inhibitor 98.99%
    Omeprazole-d3 (H 16868-d3) is deuterium labeled Omeprazole. Omeprazole, a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria.
    Omeprazole-d<sub>3</sub>
  • HY-100560S
    Abscisic acid-d6
    		Inhibitor 98.69%
    Abscisic acid-d6 is deuterium labeled Abscisic acid. Abscisic acid inhibits proton pump (H+-ATPase).
    Abscisic acid-d<sub>6</sub>
  • HY-B2145A
    Ilaprazole sodium hydrate
    		Inhibitor 99.15%
    Ilaprazole (IY-81149) sodium hydrate is an orally active proton pump inhibitor. Ilaprazole sodium hydrate irreversibly inhibits H+/K+-ATPase in a dose-dependent manner with an IC50 of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium hydrate is used for the research of gastric ulcers. Ilaprazole sodium hydrate is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor.
    Ilaprazole sodium hydrate
  • HY-108970
    Bafilomycin D
    		Inhibitor 99.30%
    Bafilomycin D is a specific inhibitor of vacuolar-type ATPase (V-ATPase). Bafilomycin D has antimicrobial, insecticidal, herbicidal and cytotoxic activity.
    Bafilomycin D
  • HY-W003467
    Rabeprazole Sulfide
    		Inhibitor 98.09%
    Rabeprazole Sulfide is an active metabolite of Rabeprazole. Rabeprazole is a proton pump inhibitor that suppresses gastric acid secretion through an interaction with (H+/K+)-ATPase in gastric parietal cells. Rabeprazole markedly inhibits the motility of H. pylori. Rabeprazole has the potential for various peptic diseases treatment.
    Rabeprazole Sulfide
  • HY-118283
    5-Hydroxylansoprazole
    		Inhibitor 99.0%
    5-Hydroxylansoprazole (AG1908) is an active metabolite of Lansoprazole in plasma. Lansoprazole is metabolized by CYP2C19 forming 5-Hydroxylansoprazole. Lansoprazole is a gastric proton-pump inhibitor and is effective in the treatment of various peptic diseases.
    5-Hydroxylansoprazole
  • HY-400540
    Padoprazanum
    		Inhibitor 98.88%
    Padoprazanum (Padoprazan) is a Proton Pump inhibitor.
    Padoprazanum
  • HY-B0113R
    Omeprazole (Standard)
    		Inhibitor
    Omeprazole (Standard) is the analytical standard of Omeprazole. This product is intended for research and analytical applications. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria.Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
    Omeprazole (Standard)
  • HY-100412
    Linaprazan
    		Inhibitor 98.80%
    Linaprazan (AZD0865) can inhibit H+,K+ -ATPase in the stomach through K+ competitive binding, (IC50: 1.0 ± 0.2 μM), it has a strong inhibitory effect on acid. Linaprazan (AZD0865) can be used for research on reflux esophagitis with oral activity.
    Linaprazan
  • HY-W317853
    Protonstatin-1
    		Inhibitor 98.47%
    Protonstatin-1 is a selective plasma membrane (PM) H+-ATPase inhibitor (IC50 of 3.9 μM) that inhibits auxin transport. Protonstatin-1 interacts with the PM H+-ATPase central loop and may thus impede the functions of the N- and/or P-domain to inhibit the pump activity.
    Protonstatin-1
  • HY-162935
    V-ATPase-IN-1
    		Inhibitor 99.23%
    V-ATPase-IN-1 (Compound 3b-03) is a Vacuolar-type H+-ATPases (V-ATPase) inhibitor (IC50 = 194.80 μM) that can effectively target the V-ATPase subunit A (Kd = 0.803 μM). V-ATPase-IN-1 exhibits insecticidal activity against M. separata (LC50 = 2.64 mM) and contributes to research in the development of chemical insecticides.
    V-ATPase-IN-1
  • HY-N7031
    (±)​-​Vasicine
    		Inhibitor 99.46%
    (±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H+-K+-ATPase activity in vitro with an IC50 of 73.47 μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant and cytoprotective effect.
    (±)​-​Vasicine
  • HY-B0113S3
    Omeprazole-13C,d3
    		Inhibitor 98.00%
    Omeprazole-13C,d3 is a 13C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868), a proton pump inhibitor (PPI), is available for treatment of acid-related gastrointestinal disorders. Omeprazole shows competitive inhibition of CYP2C19 activity with a Ki of 2 to 6 μM. Omeprazole also inhibits growth of Gram-positive and Gram-negative bacteria.Omeprazole is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).
    Omeprazole-<sup>13</sup>C,d<sub>3</sub>
  • HY-N6738
    Bafilomycin B1
    Bafilomycin B1 is a macrolide antibiotic that can be isolated from mycelium of Streptomyces gresuis. Bafilomycin B1 is neuroprotective against Chloroquine (HY-17589A)-induced death. Bafilomycin B1 is a structural analog of Bafilomycin A1 and has the ability to inhibit V-ATPase. Bafilomycin B1 inhibits significantly the oxidized low density lipoprotein (LDL)-induced accumulation of lipid droplets.
    Bafilomycin B1
  • HY-B0656S
    Rabeprazole-d4
    		Inhibitor
    Rabeprazole-d4 is a deuterium labeled Rabeprazole. Rabeprazole is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux.
    Rabeprazole-d<sub>4</sub>
Cat. No. Product Name / Synonyms Application Reactivity